Photo by: Minseong Kim / CC BY-SA (Wikimedia).

Two elderly South Korean coronavirus patients recovered from severe pneumonia after being treated with plasma from survivors, researchers said Tuesday, offering hope in the face of the global pandemic.
Scientists have pointed to the potential benefits of plasma — a blood fluid — from recovered individuals who have developed antibodies to the virus enabling the body’s defences to attack it.
Since emerging in China in December, the coronavirus has killed almost 75,000 people as drugmakers worldwide race to develop a vaccine and treatments for the disease.
Plasma therapy could become “an alternative treatment for patients in critical condition who do not respond to antiviral drugs,” said Choi Jun-yong, a doctor and researcher at Severance Hospital in Seoul, where both patients were treated.
But large-scale clinical trials were needed to prove its effectiveness, he added.
One of the two patients was a 71-year-old man with no underlying conditions who only improved when treated with plasma from a recovered patient in his 20s, along with steroids.
He was initially given malaria drugs and a respirator for severe pneumonia.
The other patient, a 67-year-old female, also did not respond to initial treatments including malaria, HIV drugs, and oxygen therapy. She began to recover after receiving plasma therapy and steroids at the same time, researchers said.
Their findings were published in the peer-reviewed Journal of Korean Medicine.
Kwon Jun-wook, an official at Seoul’s Central Disease Control Headquarters, said plasma therapy was “important” when there was “currently no vaccine or treatment available” for the virus.
He called on experts to examine the two cases urgently.
Research on plasma and other therapies “will proceed quickly”, Kwon added.
Small studies on plasma have demonstrated its effectiveness in treating infectious diseases, including Ebola and SARS.
Trials started in France on Tuesday involving 60 patients in Paris hospitals, half of whom will receive plasma from recovered patients.
The US Food and Drug Administration authorised physicians to experiment with the strategy to fight the coronavirus, and tests are also being carried out in China.
South Korea endured one of the worst early outbreaks of the virus, but appears to have brought it under control thanks to its extensive “trace, test and treat” programme.
– AFP

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments
You May Also Like

MOH confirms 48 new cases of COVID-19 infection; Total tally at 59,308

As of Sunday noon (24 Jan), the Ministry of Health (MOH) has…

Ong Ye Kung: Singapore's drop in ranking in world-talent ranking because percentage GDP spent on education dropped

The main reason why Singapore drop in ranking in the latest world-talent ranking…

SPF: Beware of impersonation of police officer scams involving fake SPF website

Singapore Police Force (SPF) alerts members of the public to a variant…

众筹两万元担保金 田柳金诉讼入禀上诉庭

曾卷入与国大诉讼持久战的田柳金(Jeanne-Marie Ten 译音),近期有意再入禀上诉庭,上诉此前高庭对其诉讼的判决。但首先她必须先支付高达两万元的担保金(security for costs)。 她目前正在网络平台发起众筹,向网民解释其诉讼来龙去脉,并吁请网民支持。她说,她必须在本月22日筹到两万元,并在26日提呈上诉通知,否则诉讼将不受理。 “据我所知,不论是英国还是马来西亚法庭,都没有所谓提成担保金的要求,但遗憾的是,这就是新加坡当前的处境。”她也非议如果在上诉陈情前还有先支付一笔费用,那么法律中保障国人有上诉的权益之意义何在? 2018年7月,高庭驳回田柳金起诉国大疏忽、违反合约、滥用职权及威胁的官司,指田没足够凭据证明指控。 但田柳金坚信,她有理由再把高庭裁决入禀到上诉庭,“在去年的书面判决,其实高庭也指国大也有不当之处”,但她认为尽管有大量文件证据,惟高庭并没有为她被开除和职涯被毁掉,要国大负起责任。 田柳金过去曾是国大设计与环境学院的硕士生,2002年入学。不过她指其导师于2004年利用她的学术研究成果,为一项个人学术作业申请津贴,尔后获教育部八万元津贴。但是之后导师拒绝在该报告中加入田的名字。 担心学术职涯受影响,当时田柳金也曾要求换导师,不过她指责校方站在导师一方,几经投诉都不得要领,她投诉到副教务长后,校方才召开调查委员会调查此事。 田柳金在2005年2月完成论文,但她表示数月后国大开出让田毕业的新条件:必须接受大学对于导师的处置。而田柳金的准硕士资格在2006年9月被剥夺。…